Korean J Pediatr Infect Dis.  2011 Jun;18(1):68-79.

Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea

• Huh JW
• Ma SH
• Kim HK
• Gunapalaiah B
• Bock HL
• Fluarix-054 Study Group

Abstract

PURPOSE
This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002.
METHODS
Eight hundred and eighty three subjects aged > or =6 months received a single dose of the vaccine; an additional dose was administered to those aged <9 years and unprimed with an influenza vaccine. Four hundred and eleven subjects used diary cards to record safety information; this report presents data from these subjects. Incidence of solicited local, general and unsolicited adverse events (4-days and 21-days post-vaccination follow-up periods, respectively) were recorded. Serious adverse events (SAEs) were recorded throughout the study period.
RESULTS
Injection site pain (subjects aged <6 years: 12.6% of subjects, > or =6 years: 34.7%), fever (<6 years: 1.3%) and myalgia (> or =6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by < or =4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria).
CONCLUSION
Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.

Keyword

Influenza vaccine; Reactogenicity; Safety

MeSH Terms

Aged
Fever
Follow-Up Studies
Humans
Immunization Programs
Incidence
Influenza Vaccines
Influenza, Human
Korea
Seasons
Vaccination
Influenza Vaccines

Reference

1. World Health Organization (WHO). Position Paper Influenza Vaccines. Wkly Epidemiol Rec. 2005. 80:277–288.

2. Influenza overview. World Health Organization (WHO). Accessed: 18 May 2010. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/.

3. Rose GW, Cooper CL. Fluarix™, inactivated split-virus influenza vaccine. Expert Opin Biol Ther. 2006. 6:301–310.

4. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine. 2008. 26S:D17–D22.

5. Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA. Facing the challenges of influenza in healthcare settings: The ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine. 2008. 26S:D27–D30.

6. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootray G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009. 58(RR-8):1–52.

7. Kim SH, Huh JH, Bae SY, Kim JS, Yoon SY, Lim CS, et al. Epidemiology of respiratory viral infection in 2004-2006. Korean J Lab Med. 2006. 26:351–357.

8. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect. 2000. 41:152–158.

9. Kim YK, Nyambat BH, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis. 2008. 40:946–953.

10. Chun BC, Woo HJ, Park SC. Preventive efficacy of influenza vaccination against to influenza-like illness among eldery. Korean J Epidemiol. 1999. 21:205–219.

11. Lee HJ. Classification of vaccination and immunization schedule recommended by the Korean Pediatric Society, 2008. J Korean Med Assoc. 2008. 51:104–109.

12. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect. 2007. 55:273–281.

13. The Korean Pediatric Society. Kang JH. [Influenza]. Immunization Guideline. 2002. 5th ed. Seoul: The Korean Pediatric Society;136–154.

14. Seo JJ, Kim MJ, Kim SH, Kee HY, Chung JK, Kim ES, et al. Characterization of respiratory viral infection in children in Gwangju. Infect Chemother. 2008. 40:218–229.

15. Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect. 2007. 135:1117–1123.

16. Nah SY, Park SE, Park JY, Lee HJ. Epidemiology of influenza virus over 8 years (1990-1998) in Seoul, Korea. Korean J Infect Dis. 1999. 31:210–216.

17. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973. 288:498–505.

18. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005. 1:239–244.

19. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest. 2002. 22:751–769.

20. El Sahly HM, Keitel WA. Clinical data on Fluarix™: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008. 7:713–719.

21. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008. 359:1555–1564.

22. Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-Protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology. 2007. 50:58–62.